@article{JGO4215,
author = {Tolutope Oyasiji and Wen Wee Ma},
title = {Novel adjuvant therapies for pancreatic adenocarcinoma},
journal = {Journal of Gastrointestinal Oncology},
volume = {6},
number = {4},
year = {2015},
keywords = {},
abstract = {Contemporary adjuvant therapy for pancreatic cancer patients following surgical resection includes chemotherapy and chemoradiotherapy. However, the median survival remains approximately 20 months despite multi-modality treatment using gemcitabine or fluoropyrimidine systemic chemotherapy. Adjuvant randomized trials are currently underway to evaluate cytotoxic combinations found to be active in advanced disease including FOLFIRINOX, gemcitabine/nab-paclitaxel and gemcitabine/capecitabine. Immunotherapy using genetically engineered cell-based vaccines had shown promise in resected pancreatic cancer patients during early phase trials, and algenpantucel-L vaccine is currently being evaluated in adjuvant setting in a randomized trial. This review focuses on novel adjuvant therapies currently in clinical evaluation.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/4215}
}